DelMar Pharmaceuticals (NASDAQ:DMPI) released its quarterly earnings data on Thursday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.03, Fidelity Earnings reports.
NASDAQ DMPI opened at $0.55 on Friday. DelMar Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $6.29. The business has a 50 day moving average price of $0.59 and a two-hundred day moving average price of $0.71. The stock has a market cap of $6.27 million, a PE ratio of -0.29 and a beta of 1.30.
A number of brokerages have commented on DMPI. Maxim Group restated a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Friday, November 15th. Zacks Investment Research upgraded DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Story: Stocks at 52 Week High
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.